ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics gross margin
Gross margin is gross profit as a percentage of revenue.
ADMA Biologics's gross margin for the twelve months ending Jun 30, 2026 was 64.7%. For fiscal 2025 it was 57.4%, against 51.5% the year before. The highest annual figure on record is 72.7% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.4% | +5.9 |
| FY2024 | Dec 31, 2024 | 51.5% | +17.0 |
| FY2023 | Dec 31, 2023 | 34.4% | +11.6 |
| FY2022 | Dec 31, 2022 | 22.9% | +21.4 |
| FY2021 | Dec 31, 2021 | 1.4% | +46.6 |
| FY2020 | Dec 31, 2020 | -45.2% | −10.6 |
| FY2019 | Dec 31, 2019 | -34.6% | +113.8 |
| FY2018 | Dec 31, 2018 | -148.4% | −120.3 |
| FY2017 | Dec 31, 2017 | -28.1% | −68.5 |
| FY2016 | Dec 31, 2016 | 40.3% | +0.4 |
| FY2015 | Dec 31, 2015 | 39.9% | +3.2 |
| FY2014 | Dec 31, 2014 | 36.7% | +2.7 |
| FY2013 | Dec 31, 2013 | 34.0% | −6.1 |
| FY2012 | Dec 31, 2012 | 40.2% | −32.6 |
| FY2011 | Dec 31, 2011 | 72.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 69.4% | +14.2 |
| Q1 FY2026 | Mar 31, 2026 | 70.5% | +17.3 |
| Q4 FY2025 | Dec 31, 2025 | 63.8% | +9.9 |
| Q3 FY2025 | Sep 30, 2025 | 56.3% | +6.6 |
| Q2 FY2025 | Jun 30, 2025 | 55.1% | +1.5 |
| Q1 FY2025 | Mar 31, 2025 | 53.2% | +5.5 |
| Q4 FY2024 | Dec 31, 2024 | 53.9% | +11.8 |
| Q3 FY2024 | Sep 30, 2024 | 49.8% | +13.1 |
| Q2 FY2024 | Jun 30, 2024 | 53.6% | +25.8 |
| Q1 FY2024 | Mar 31, 2024 | 47.8% | +18.8 |
| Q4 FY2023 | Dec 31, 2023 | 42.1% | +13.7 |
| Q3 FY2023 | Sep 30, 2023 | 36.6% | +13.1 |
| Q2 FY2023 | Jun 30, 2023 | 27.8% | +4.8 |
| Q1 FY2023 | Mar 31, 2023 | 29.0% | +16.4 |
| Q4 FY2022 | Dec 31, 2022 | 28.4% | +15.1 |
| Q3 FY2022 | Sep 30, 2022 | 23.5% | +21.6 |
| Q2 FY2022 | Jun 30, 2022 | 22.9% | +28.5 |
| Q1 FY2022 | Mar 31, 2022 | 12.6% | +23.3 |
| Q4 FY2021 | Dec 31, 2021 | 13.3% | +50.2 |
| Q3 FY2021 | Sep 30, 2021 | 1.9% | +17.2 |
| Q2 FY2021 | Jun 30, 2021 | -5.6% | +67.7 |
| Q1 FY2021 | Mar 31, 2021 | -10.7% | +54.3 |
| Q4 FY2020 | Dec 31, 2020 | -36.9% | −39.8 |
| Q3 FY2020 | Sep 30, 2020 | -15.4% | −5.8 |
| Q2 FY2020 | Jun 30, 2020 | -73.3% | −13.4 |
| Q1 FY2020 | Mar 31, 2020 | -65.0% | +101.5 |
| Q4 FY2019 | Dec 31, 2019 | 2.9% | +177.5 |
| Q3 FY2019 | Sep 30, 2019 | -9.6% | +107.0 |
| Q2 FY2019 | Jun 30, 2019 | -59.9% | +47.2 |
| Q1 FY2019 | Mar 31, 2019 | -166.5% | +36.3 |
| Q4 FY2018 | Dec 31, 2018 | -174.7% | −175.3 |
| Q3 FY2018 | Sep 30, 2018 | -116.6% | +22.1 |
| Q2 FY2018 | Jun 30, 2018 | -107.1% | −79.6 |
| Q1 FY2018 | Mar 31, 2018 | -202.9% | −241.4 |
| Q4 FY2017 | Dec 31, 2017 | 0.7% | −38.8 |
| Q3 FY2017 | Sep 30, 2017 | -138.7% | −179.7 |
| Q2 FY2017 | Jun 30, 2017 | -27.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 38.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 39.5% | – |
| Q3 FY2016 | Sep 30, 2016 | 40.9% | – |
See a number that looks wrong?